世界の催吐性薬市場 – 業界動向と2030年までの予測

催吐性薬物市場の分析と規模

新興経済国は、医療インフラの拡大により、催吐剤の主要市場となっています。世界的に癌や胃腸炎の発生が増加し、研究開発活動が増加し、いくつかの新しい薬剤ターゲットが特定されたことが、市場の成長にプラスの影響を与えています。薬剤は、静脈内、筋肉内、皮下注射など、さまざまな形で入手できます。

データブリッジ市場調査は、2023年から2030年の予測期間における催吐性薬市場の成長率を分析しています。催吐性薬市場の予想CAGRは、上記の予測期間において約14.2%になる傾向があります。市場は2022年に13億7,150万米ドルと評価され、2030年までに39億6,757万米ドルまで成長すると予想されています。市場価値、成長率、市場セグメント、地理的範囲、市場プレーヤー、市場シナリオなどの市場洞察に加えて、データブリッジ市場調査チームがまとめた市場レポートには、詳細な専門家分析、患者疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

催吐性薬物市場の範囲とセグメンテーション

Market Definition

Emetogenic symptoms are associated with nausea and vomiting related to the cancer treatment such as chemotherapy, radiation therapy and drug therapy. Nausea and vomiting are the major side effects of cancer therapy. It is significant that nausea and vomiting must be controlled so the patient can continue the treatment and have a better quality of life. Majorly nausea and vomiting induced by patients on chemotherapy and radiation therapy of the brain, gastrointestinal tract, or liver also cause nausea and vomiting.

Global Emetogenic Drugs Market Dynamics

Drivers

• High Prevalence of Cancer

As per the Cancer Statistics by the National Cancer Institute, in 2020, an assessed 1,806,590 new cases of cancer were diagnosed in the U.S. and 606,520 people died from the disease. An estimated 16,850 children and adolescents aged between 0 to 19 years were diagnosed with cancer, and 1,730 died of the same disease. Likewise, the Centers for Disease Control and Prevention reported around 179 million cases of acute gastroenteritis (AGE) occur annually in the U.S.. In the U.S. and other regions, 2-23% of children with acute gastroenteritis are treated with antiemetics, as per the reports of the American Academy of Pediatrics, 2020.

• Launch of New Drugs

Several drug launches by top market players boost the growth of the market. For instance, in September 2020, Sandoz, a Novartis division, launched generic Fosaprepitant, an anti-emetic drug used to prevent nausea and vomiting induced by chemotherapy in the U.S., increasing hospital offerings and strategically intensifying its injectables portfolio.

Opportunities

• Increased Strategic Alliances Between Market Players

There have been strategic activities such as product development, mergers, approvals, and acquisitions by major market players operating within the market are expected to boost the segment growth throughout the forecast period. For instance, in January 2022, Cumberland Pharmaceuticals, which is a specialty pharmaceutical company, acquired Sancuso, which is an oncology-supportive care medicine from Kyowa Kirin North America. Sancuso is the first and only FDA-approved Granisetron transdermal prescription patch used for the prevention of nausea and vomiting in patients who are  receiving different types of chemotherapy treatment.

• Rising Demand of Oral Drugs

Oral emetogenic drugs are crating a greater market space as they prevent or treat nausea and vomiting. They work by blocking signals from the brain to the stomach which can cause these symptoms. There are several types of drugs such as ondansetron, prochlorperazine, and metoclopramide.

Restraints/Challenges

• High Cost of Emetogenic Drugs

The huge cost associated with these drugs hamper the growth of the market. There are various drugs such as Neurokinin-1 Receptor Antagonist (NK1 RAS), 5HT3 RA/NK1 RA combination, corticosteroids which cost quite high and thus restrict the marke growth.

This emetogenic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the emetogenic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Emetogenic Drugs Market

The COVID-19 pandemic has had a positive impact on the emetogenic drugs market. The increased cases of SARS-CoV-2 have increased the use of antiemetics to treat nausea and vomiting induced by COVID-19 or any other medication. For instance, in a study titled "Current Knowledge and recent advances in Intracellular Emetic Signaling System" published in The International Journal of Clinical Practice, 2021, it was witnessed that the use of antiemetics was majorly increased during COVID-19 to treat nausea and vomiting. It was also used in COVID-19 hospitalized patients who might be undergoing open surgery and thus more prone to nausea and vomiting. Thus, the COVID-19 outbreak positively impacted the market growth.

Recent Development

• In April 2022, Evoke Pharma, Inc., was granted new drug product exclusivity by the U.S. FDA for Gimoti nasal spray. Evoke now has exclusive marketing privileges over three years from the initial approval date under the Hatch-Waxman Act to protect the product from generic drug competition. Metoclopramide is a dopamine antagonist WHICHis used as a potent antiemetic drug
• In February 2022, Acacia Pharmaceutical’s Barhemsys received US-FDA approval. It is an intravenous formulation of amisulpride for the treatment of postoperative nausea and vomiting in patients that didn’t respond to treatment with an antiemetic from a different class. The company is in commercial preparations and is expected to launch Barhemsys in the second half of 2022.

Global Emetogenic Drugs Market Scope

The emetogenic drugs market is segmented on the basis of class, types of emesis, application, drug type, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Class

• Serotonin Receptor Antagonists (5-HT3 RAS)
• Neurokinin-1 Receptor Antagonist (NK1 RAS)
• 5HT3 RA/NK1 RA Combination
• Corticosteroids
• Olanzapine
• Others

Types of Emesis

• Acute
• Delayed
• Anticipatory
• Breakthrough
• Refractory
• Chronic
• Others

Application

• Highly Emetogenic Chemotherapy
• Moderately Emetogenic Chemotherapy
• Low Emetogenic Chemotherapy
• Other

Drug Type

• Branded
• Generic

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Emetogenic Drugs Market Regional Analysis/Insights

The emetogenic drugs market is analyzed and market size insights and trends are provided by class, types of emesis, application, drug type,  end-user and distribution channel as referenced above.

The major countries covered in the emetogenic drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to increased healthcare and R&D expenditure and presence of skilled professionals

Asia-Pacific is expected to account for the largest market share due to increased prevalence of cancer and rapidly improving healthcare infrastructure in the region.

レポートの国別セクションでは、市場の現在および将来の動向に影響を与える国内市場における個別の市場影響要因と規制の変更についても説明しています。また、国別データの予測分析を提供しながら、グローバルブランドの存在と入手可能性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されています。   

競争環境と世界の催吐性薬市場シェア分析

催吐性薬物市場の競争環境は、競合他社ごとに詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性が含まれます。提供されている上記のデータポイントは、催吐性薬物市場に関連する会社の焦点にのみ関連しています。

催吐性薬市場で活動している主要企業は次のとおりです。

• ヘロン・セラピューティクス社（米国）
• サンドス・インターナショナル GmbH (スイス)
• メルク社（米国）
• エーザイ株式会社（日本）
• テバ製薬工業株式会社（イスラエル）
• 斉魯製薬株式会社（中国）
• F.ホフマン・ラ・ロシュ社（スイス）
• マイランNV（米国）
• GSK plc（英国）
• ムンディファーマ・インターナショナル（英国）
• バクスター（米国）
• バイエルAG（ドイツ）
• シプラ社（米国）
• サノフィ（フランス）
• サン・ファーマシューティカル・インダストリーズ（インド）

SKU-57254